Ang Ⅱ 对培养新生大鼠心肌成纤维细胞增殖及丝裂素活化蛋白激酶的影响

本研究目的在于探讨丝裂素活化蛋白激酶（ＭＡＰＫ）是否在ＡｎｇⅡ（１０－８ｍｏｌ／Ｌ）诱导的培养新生大鼠心肌成纤维细胞（ＦＢ）的增殖反应中起重要作用。实验以ＦＢ数目和ＤＮＡ合成速率（３Ｈ－胸腺嘧啶掺入率）为增殖指标,［γ－３２Ｐ］ＡＴＰ掺入法和免疫印迹法分别测定ＦＢＭＡＰＫ的活性和含量,结果发现（１）ＡｎｇⅡ处理ＦＢ２４ｈ后,ＤＮＡ合成速率和细胞数比对照组分别增加６０％和３９％;（２）ＡｎｇⅡ处理ＦＢ５ｍｉｎ后,ＭＡＰＫ活性比对照组增高２０３％;（３）培养新生大鼠ＦＢ含有两个ＭＡＰＫ同型体－ｐ４４ｍａｐｋ和ｐ４２ｍａｐｋ,其中ｐ４４ｍａｐｋ含量高于ｐ４２ｍａｐｋ,分别为总量的５８％和４２％。ＡｎｇⅡ处理５ｍｉｎ后,ＭＡＰＫ蛋白含量（ｐ４４＋ｐ４２〕增高４２９％,其中ｐ４４ｍａｐｋ的增加明显大于ｐ４２ｍａｐｋ的增加,分别比相应对照增高４８６％和３４９％。以上结果表明,ＡｎｇⅡ诱导的ＭＡＰＫ活性和含量的增加,参与了ＦＢ的增殖反应,其中ｐ４４ｍａｐｋ的作用较为显著     

RFP_（134）对UMR106细胞EGF受体酪氨酸蛋白激酶的调节作用

以大鼠成骨肉瘤细胞（ＵＭＲ１０６）为模型,研究了表皮生长因子（ＥＧＦ）对其受体酪氨酸蛋白激酶（ＴＰＫ）的调节作用。以本实验室从植物中提取纯化的二萜类活性物质（ＲＦＰ１３４）为诱导分化剂,观察了ＲＦＰ１３４对ＵＭＲ１０６细胞ＥＧＦ受体ＴＰＫ的活性和磷酸化作用的影响,并与ＲＡ和ＲＦＰ１３４＋ＲＡ处理细胞做了比较,结果显示ＥＧＦ与其受体结合后能激活ＴＰＫ,使ＴＰＫ活性增加２倍．ＲＦＰ１３４,ＲＡ,ＲＦＰ１３４＋ＲＡ处理细胞后,分别降低ＥＧＦ诱导的受体ＴＰＫ活性５０％,４３％,５５％,降低磷酸化ＴＰＫ含量５５％,３６％,５３％。从结果中发现无ＥＧＦ刺激的细胞也具有受体ＴＰＫ磷酸化作用,用ＲＦＰ１３４,ＲＡ,ＲＦＰ１３４＋ＲＡ处理细胞,分别降低受体磷酸化ＴＰＫ含量５９％,４０％,５７％,而且我们发现用ＥＧＦ诱导的细胞受体ＴＰＫ含量高于无ＥＧＦ作用的细胞．提示ＵＭＲ１０６细胞本身可能具有受体ＴＰＫ活性,能够引起细胞受体自动磷酸化,ＥＧＦ刺激后ＴＰＫ的磷酸化作用增强,可见ＲＦＰ１３４对ＥＧＦ诱导的ＴＰＫ磷酸化和无ＥＧＦ诱导的受体自动磷酸化都具有明显的抑制作用,（并强于ＲＡ）这可能与在第二信使水平上阻抑ＰＴＰＫ活性密切相关     

人主动脉硫酸乙酰肝素蛋白聚糖对培养的人血管壁细胞生长的作用

通过培养的人主动脉平滑肌细胞（ｈＡＳＭＣ）及脐静脉内皮细胞（ｈＵＶＥＣ）,应用３Ｈ－ＴｄＲ参入、Ｎｏｒｔｈｅｒｎｂｌｏｔ分析、逆转录多聚酶链反应（ＲＴ－ＰＣＲ）、放射免疫分析（ＲＩＡ）、和紫外比色法等技术观察了人主动脉中硫酸乙酰肝素蛋白聚糖（ＨＳＰＧ）对ｈＡＳＭＣ和ｈＵＶＥＣＤＮＡ合成的作用及对血小板源生长因子（ＰＤＧＦ）、ＰＤＧＦ受体、转化生长因子β（ＴＧＦ－β）、内皮素－１（ＥＴ－１）或碱性成纤维细胞生长因子（ｂＦＧＦ）基因表达和肾素－血管紧张系统（ＲＡＳ）的影响,结果显示,ＨＳＰＧ明显抑制培养的ｈＡＳＭＣ基础的ＤＮＡ合成（ｃｐｍ值为：１０３８５±３２６３ｖｓ,２５５４１±６４２１,Ｐ＜０．０１）及外源性ＰＤＧＦ诱导的ＤＮＡ合成（ｃｐｍ值为：９８７８±１９４７ｖｓ．１３４８１±４４ｌ０,Ｐ＜０．０５）;抑制ＰＤＧＦＡ链、ＴＧＦ－Ｂｐ和ＥＴ－１ｍＲＮＡ表达,提高ＰＤＧＦａ和β受体ｍＲＮＡ的表达;显著降低ｈＡＳＭＣ培养液中血管紧张素Ⅱ（ＡｎｇⅡ）的浓度和血管紧张素转换酶（ＡＣＥ）的活性,推测ＨＳＰＧ抑制ＰＤＧＦＡ链、ＴＧＦ－β及ＥＴ－１ｍＲＮＡ表达,降低ＡＣＥ活性及ＡｎｇⅡ浓度是其抑制ｈＡＳＭＣ增殖的重要机     

RFP134对UMR106细胞EGF受体酪氨酸蛋白激酶的调节作用

以大鼠成骨肉瘤细胞（ＵＭＲ１０６）为模型,研究了表皮生长因子（ＥＧＦ）对其受体酪氨酸蛋白激酶（ＴＰＫ）的调节作用。以及实验室从植物中提取纯化的二萜类活性物质（ＲＦＰ１３４）为诱导分化剂,观察了ＲＦＰ１３４对ＵＭＰ１０６细胞ＥＧＦ受体ＴＰＫ的活性和磷酸化作用的影响。并与ＲＡ和ＲＦＰ１３４＋ＲＡ处理细胞做了比较。结果显示ＥＧＦ与其受体结合后能激活ＴＰＫ,使ＴＰＫ活性增加２倍。ＲＦＰ１３４,ＲＡ,ＲＦＰ     

细支气管肺泡细胞增生和细支气管肺泡细胞癌内生长因子和蛋白激酶C的表达

表皮生长因子（ＥＧＦ）、转化生长因子－α（ＴＧＦα）、表皮生长因子受体（ＥＧＦＲ）和蛋白激酶Ｃ（ＰＫＣ）与细胞生长、增殖分化调节和细胞癌变有密切关系。作者用免疫组织化学方法检测了细支气管肺泡细胞增生（ＢＡＨ）和细支气管肺泡细胞癌（ＢＡＣ）的ＥＧＦ、ＴＧＦα、ＥＧＦＲ和ＰＫＣ表达。结果表明：ＢＡＣ中的ＥＧＦ、ＴＧＦα阳性率和阳性强度以及ＥＧＦＲ、ＰＫＣ阳性强度均明显高于ＢＡＨ。ＢＡＨ的重度不典型增生病例,其ＥＧＦ、ＴＧＦα、ＥＧＦＲ和ＰＫＣ均呈高表达。ＴＧＦα、ＥＧＦＲ和ＰＫＣ三者在ＢＡＣ和ＢＡＨ中的表达存在明显相关性。提示：ＴＧＦα及其受体ＥＧＦＲ和ＰＫＣ是细支气管肺泡细胞增生、恶性转化和肺泡癌细胞失控生长的重要因素。     

血管平滑肌细胞增殖与Cdk抑制蛋白p27的表达

ｐ２７蛋白是细胞周期素依赖性激酶（Ｃｄｋ）抑制蛋白家族中的一种,主要对外部促进或抑制细胞增殖的信号起反应。本研究应用流式细胞仪（ＦＣＭ）双标记的方法观察血管紧张素Ⅱ（ＡｎｇⅡ）、血管加压素（ＡＶＰ）和血小板源生长因子（ＰＤＧＦ）对血管平滑肌细胞（ＶＳＭＣｓ）细胞周期百分比和ｐ２７蛋白表达量的影响。静止状态培养的ＶＳＭＣｓ加入ＡｎｇⅡ,ＡＶＰ,ＰＤＧＦＢＢ后,在不同时间收集细胞,用碘化丙啶（ＰＩ）标记细胞ＤＮＡ,以确定细胞所处的周期。用ｐ２７蛋白的单抗和标记了ＦＩＴＣ的二抗标记细胞,通过流式细胞仪测定被激发出的荧光量来确定细胞ｐ２７蛋白表达的相对量。结果显示,ＡｎｇⅡ刺激ＶＳＭＣｓ增生,其蛋白含量增加了４３６％（Ｐ＜００１）,但不抑制ｐ２７蛋白的表达;ＡＶＰ可轻度抑制ｐ２７的表达,有轻度促进ＶＳＭＣｓ增殖和增生的作用（Ｐ＜００５）;ＰＤＧＦ明显抑制ｐ２７的表达,引起细胞增殖。本研究结果提示,ｐ２７蛋白抑制ＶＳＭＣｓ通过Ｇ１期进入Ｓ期,是抑制ＶＳＭＣｓ增殖的重要调节因子。     

几种扩血管多肽对bFGF促血管平滑肌细胞增殖作用的影响

目的和方法：研究肾上腺髓质素（Ａｄｍ）、降钙素基因相关肽（ＣＧＲＰ）及Ｃ－型心房利太（ＣＮＰ）对碱性成纤维细胞生长因子（ｂＦＧＦ）促血管平滑细胞（ＶＳＭＣ）增殖作用的影响及其机制。结果：孵育２４ｈ后,ｂＦＧＦ刺激ＶＳＭＣ增殖较对照组增加２．１倍（Ｐ〈０．０１）,细胞内蛋白磷酸化程度增加１．４倍（Ｐ〈０．０１）,ＰＫＣ及ＭＡＰＫ活性分别增加１．５和２．５倍（Ｐ〈０．０１０;Ａｄｍ．ＣＧＲＰｔ ＣＮＰ     

自发性高血压大鼠心肌肥厚和心肌MAPK、AngⅡ的关系

放免法测定自发性高血压大鼠（ＳＨＲ）血浆及心肌血管紧张素Ⅱ（ＡｎｇⅡ）含量,凝胶内磷酸化法测定心肌丝裂素活化蛋白激酶活性（ＭＡＰＫ）,以心脏重／体重表示心肌肥厚程度。结果表明：与４个月的ＷＫＹ大鼠比较,４个月的ＳＨＲ血浆和心肌组织ＡｎｇⅡ及心肌ＭＡＰＫ活性分别增加了２１８．６％、１０１．２％和１０７．０％,心肌肥大程度严重,其中ＭＡＰＫ活性与心肌肥大程度呈明显正相关。提示４个月ＳＨＲ心肌肥厚可能是     

MKP—1在血管紧张素Ⅱ导致心肌肥大反应中的调控作用

本研究主要从丝裂原活化蛋白激酶磷酸酶－１（ＭＫＰ－１）角度,研究丝裂原活化蛋白激酶（ＭＡＰＫ）信号途径在血管紧张素Ⅱ介导的新生大鼠心肌细胞肥大反应中的作用及调控机制。实验以心肌细胞蛋白合成速率、蛋白含量及细胞表面积作为心肌肥大反应的指标,以凝胶内ＭＢＰ原位磷酸化测定ＭＡＰＫ活性,以免疫印迹法（Ｗｅｓｔｅｒｎ ｂｏｌｔｔｉｎｇ）分别测定ＭＫＰ－１及磷酸化ｐ４４ＭＡＰＫ、ｐ４２ＭＡＰＫ蛋白表达。结果发     

丝裂素活化蛋白激酶参与内皮素刺激的兔主动脉平滑肌细胞增生

内皮素（ｅｎｄｏｔｈｅｌｉｎ,ＥＴ）是已知的体内活性最强的缩血管物质,其缩血管作用由Ｇ蛋白偶联受体所介导。但ＥＴ强大的促血管平滑肌细胞（ＶＳＭＣ）增生效应的机理尚未完全阐明。本研究选用培养的兔胸主动脉ＶＳＭＣ,探讨丝裂素活化蛋白激酶（ＭＡＰＫ）在ＥＴ促细胞增生中的作用。结果表明：ＥＴ－１呈时间和浓度依赖性地促进细胞摄取￣３Ｈ－ＴｄＲ和激活ＭＡＰＫ,此作用可被蛋白激酶Ｃ（ｐｒｏｔｅｉｎｋｉｎａｓｅＣ,ＰＫＣ）抑制剂Ｓｔａｕｒｏｓｐｏｒｉｎｅ（ＳＴＰ）,Ｈ－７和ＥＴ＿Ａ受体拮抗剂ＢＱ１２３所抑制,但不被酪氨酸激酶抑制剂ＨｅｒｂｉｍｙｃｉｎＡ（Ｈｅｒｂ）所抑制,用ＰＫＣ激动剂ＰＭＡ（Ｐｈｏｒｂｏｌｍｙｒｉｓｔａｔｅａｃｅｔａｔｅ）预处理ＶＳＭＣ,使其ＰＫＣ活性下调,可显著减弱ＥＴ－１对ＭＡＰＫ的激活能力。本结果提示：（１）ＭＡＰＫ参与ＥＴ－１所致的ＶＳＭＣ增生;（２）ＥＴ－１促细胞增生与激活ＭＡＰＫ的作用是由ＥＴ＿Ａ受体和ＰＫＣ介导的。     

Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK

In cultured vascular smooth muscle cells (VSMC), the vasculotrophic factor, angiotensin II (AngII) activates three major MAPKs via the G(q)-coupled AT1 receptor. Extracellular signal-regulated kinase (ERK) activation by AngII requires Ca(2+)-dependent "transactivation" of the EGF receptor that may involve a metalloprotease to stimulate processing of an EGF receptor ligand from its precursor. Whether EGF receptor transactivation also contributes to activation of other members of MAPKs such as p38MAPK and c-Jun N-terminal kinase (JNK) by AngII remains unclear. In the present study, we have examined the effects of a synthetic metalloprotease inhibitor BB2116, and the EGF receptor kinase inhibitor AG1478 on AngII-induced activation of MAPKs in cultured VSMC. BB2116 markedly inhibited ERK activation induced by AngII or the Ca(2+) ionophore without affecting the activation by EGF or PDGF. BB2116 as well as HB-EGF neutralizing antibody inhibited the EGF receptor transactivation by AngII, suggesting a critical role of HB-EGF in the metalloprotease-dependent EGF receptor transactivation. In addition to the ERK activation, activation of p38MAPK and JNK by AngII was inhibited by an AT1 receptor antagonist, RNH6270. and EGF markedly activate p38MAPK, whereas but not EGF markedly activates JNK, indicating the possible contribution of the EGF receptor transactivation to the p38MAPK activation. The findings that both BB2116 and AG1478 specifically inhibited activation of p38MAPK but not JNK by AngII support this hypothesis. From these data, we conclude that ERK and p38MAPK activation by AngII requires the metalloprotease-dependent EGF receptor transactivation, whereas the JNK activation is regulated without involvement of EGF receptor transactivation.     

Insulin-activated protein kinase Cbeta bypasses Ras and stimulates mitogen-activated protein kinase activity and cell proliferation in muscle cells

In L6 muscle cells expressing wild-type human insulin receptors (L6hIR), insulin induced protein kinase Calpha (PKCalpha) and beta activities. The expression of kinase-deficient IR mutants abolished insulin stimulation of these PKC isoforms, indicating that receptor kinase is necessary for PKC activation by insulin. In L6hIR cells, inhibition of insulin receptor substrate 1 (IRS-1) expression caused a 90% decrease in insulin-induced PKCalpha and -beta activation and blocked insulin stimulation of mitogen-activated protein kinase (MAPK) and DNA synthesis. Blocking PKCbeta with either antisense oligonucleotide or the specific inhibitor LY379196 decreased the effects of insulin on MAPK activity and DNA synthesis by >80% but did not affect epidermal growth factor (EGF)- and serum-stimulated mitogenesis. In contrast, blocking c-Ras with lovastatin or the use of the L61,S186 dominant negative Ras mutant inhibited insulin-stimulated MAPK activity and DNA synthesis by only about 30% but completely blocked the effect of EGF. PKCbeta block did not affect Ras activity but almost completely inhibited insulin-induced Raf kinase activation and coprecipitation with PKCbeta. Finally, blocking PKCalpha expression by antisense oligonucleotide constitutively increased MAPK activity and DNA synthesis, with little effect on their insulin sensitivity. We make the following conclusions. (i) The tyrosine kinase activity of the IR is necessary for insulin activation of PKCalpha and -beta. (ii) IRS-1 phosphorylation is necessary for insulin activation of these PKCs in the L6 cells. (iii) In these cells, PKCbeta plays a unique Ras-independent role in mediating insulin but not EGF or other growth factor mitogenic signals.     

Protein phosphatase 2A regulatory subunit Bbeta promotes MAP kinase-mediated migration of A431 cells.

BACKGROUND/AIMS: Phosphatases are involved in regulation of MAP kinase (MAPK). A431 cells migrate on collagen after EGF stimulation using MAPK. To clarify the involvement of PP2A in this MAPK-dependent migration, the expression of an isoform of the B regulatory subunit was inhibited. METHODS: An antisense sequence corresponding to Bbeta cDNA was transfected into A431 cells. Their migratory activity on collagen was examined using Transwell, and MAPK phosphorylation and phosphatase activity were measured, and the results were compared with those obtained with mock-transfected cells. RESULTS: Antisense-transfected cells showed less Bbeta protein and phosphatase activity than mock-transfected controls. Migration of antisense-transfected cells showed a low response to EGF. The response of MAPK phosphorylation of antisense-transfected cells to EGF stimulation and adhesion to collagen in the presence or absence of EGF were markedly decreased. Phosphatase activity of PP2A-Bbeta also did not respond to EGF, collagen or EGF plus collagen, and remained at low levels. CONCLUSION: These results suggested that PP2A-Bbeta promotes cell migration through the MAPK cascade.     

Selective modulation of MAP kinase in embryonic palate cells

Murine embryonic palate mesenchyme (MEPM) cells are responsive to a number of endogenous factors found in the local embryonic tissue environment. Recently, it was shown that activation of the cyclic AMP (cAMP) or the transforming growth factor β (TGFβ) signal transduction pathways modulates the proliferative response of MEPM cells to epidermal growth factor (EGF). Since the mitogen-activated protein kinase (MAPK) cascade is a signal transduction pathway that mediates cellular responsiveness to EGF, we examined the possibility that several signaling pathways which abrogate EGF-stimulated proliferation do so via the p42/p44 MAPK signaling pathway. We demonstrate that EGF stimulates MAPK phosphorylation and activity in MEPM cells maximally at 5 minutes. Tyrosine phosphorylation and activation of MAPK was unaffected by treatment of MEPM cells with TGFβ or cholera toxin. Similarly, TGFβ altered neither EGF-induced MAPK tyrosine phosphorylation nor activity. However, the calcium ionophore, A23187, significantly increased MAPK phosphorylation which was further increased in the presence of EGF, although calcium mobilization reduced EGF-induced proliferation. Despite the increase in phosphorylation, we could not demonstrate induction of MAPK activity by A23187. Like EGF, phorbol ester, under conditions which activate PKC isozymes in MEPM cells, increased MAPK phosphorylation and activity but was also growth inhibitory to MEPM cells. The MEK inhibitor, PD098059, only partially abrogated EGF-induced phosphorylation. Likewise, depletion of PKC isozymes partially abrogated EGF-induced MAPK phosphorylation. Inhibition of both MEK and PKC isozymes resulted in a marked decrease in MAPK activity, confirming that EGF uses multiple pathways to stimulate MAPK activity. These data indicate that the MAPK cascade does not mediate signal transduction of several agents that inhibit growth in MEPM cells, and that there is a dissociation of the proliferative response and MAP kinase activation. Furthermore, other signaling pathways known to play significant roles in differentiation of palatal tissue converge with the MAPK cascade and may use this pathway in the regulation of alternative cellular processes. J. Cell. Physiol. 176:266–280, 1998. © 1998 Wiley-Liss, Inc.     

Role of cAMP inhibition of p44/p42 mitogen-activated protein kinase in potentiation of protein secretion in rat lacrimal gland

We previously found that addition of cAMP and a Ca(2+)/PKC-dependent agonist causes synergism or potentiation of protein secretion from rat lacrimal gland acini. In the present study we determined whether cAMP decreases p44/p42 mitogen-activated protein kinase (MAPK) activity in the lacrimal gland. Since we know that activation of MAPK attenuates protein secretion stimulated by Ca(2+)- and PKC-dependent agonists, we also determined whether this activation causes potentiation of secretion. Freshly prepared rat lacrimal gland acinar cells were incubated with dibutyryl cAMP (DBcAMP), carbachol (a cholinergic agonist), phenylephrine (an alpha(1)-adrenergic agonist), or epidermal growth factor (EGF). The latter three agonists are known to activate p44/p42 MAPK. p44/p42 MAPK activity and protein secretion were measured. As measured by Western blot analysis, DBcAMP inhibited both basal and agonist-stimulated p44/p42 MAPK activity. Cellular cAMP levels were increased by 1) using two different cell-permeant cAMP analogs, 2) activating adenylyl cyclase (L-858051), or 3) activation of G(s)-coupled receptors (VIP). The cell-permeant cAMP analogs, L-858051, and VIP inhibited basal p44/p42 MAPK activity by 50, 40, and 40%, respectively. DBcAMP and VIP inhibited carbachol- and EGF-stimulated MAPK activity. cAMP, but not VIP, inhibited phenylephrine-stimulated MAPK activity. Potentiation of secretion was detected when carbachol, phenylephrine, or EGF was simultaneously added with DBcAMP. We conclude that increasing cellular cAMP levels inhibits p44/p42 MAPK activity and that this could account for potentiation of secretion obtained when cAMP was elevated and Ca(2+) and PKC were increased by agonists.     

Effects of dehydroepiandrosterone on mitogen-activated protein kinase in human aortic smooth muscle cells.

The objective of the present study was to determine whether dehydroepiandrosterone (DHEA) modifies growth factor-induced mitogen-activated protein kinase (MAPK) activation, based on our previous study demonstrating that DHEA attenuates fetal calf serum-induced proliferation in human male aortic smooth muscle cells (human male aortic SMCs). Human male aortic SMCs were used for this study. Platelet-derived growth factor-BB (PDGF-BB), epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF), but not insulin-like growth factor-1 (IGF-1), stimulated MAPK activity. Only MAPK activation induced by PDGF-BB was reduced by pretreatment with DHEA, although DHEA did not affect the MAPK activation induced by EGF or bFGF. The basal and PDGF-stimulated MAPK activity were decreased by two types of cyclic AMP (cAMP) elevating agents and increased by cAMP-dependent protein kinase (PKA) inhibitor in human male aortic SMCs, suggesting that cAMP regulates MAPK negatively. The intracellular cAMP was increased by PDGF-BB. The increase of cAMP by PDGF-BB was augmented by pretreatment with DHEA, although DHEA alone did not affect cAMP. Neither EGF nor bFGF affected cAMP with and without DHEA pretreatment. Secretion of PGE2 induced by PDGF was augmented by pretreatment with DHEA. Stimulatory effects of DHEA on the production of PGE2 and cAMP were partially canceled by aromatase inhibitor and completely canceled by indomethacin or selective inhibitor of cyclooxygenase-2. These results suggest that DHEA inhibited MAPK activation induced by PDGF-BB via PGE2 overproduction and subsequent cAMP-dependent pathway in human male aortic SMCs.     

白介素-10抑制TNF-α诱导的血管平滑肌细胞增殖

研究观察了重组人白介素 10 (rhIL 10 )对肿瘤坏死因子 (TNF α)刺激的离体大鼠胸主动脉血管平滑肌细胞增殖、细胞周期及对p4 4 /p4 2丝裂素活化蛋白激酶的影响。实验培养大鼠主动脉血管平滑肌细胞 ,采用MTS/PES法确定血管平滑肌细胞 (vascularsmoothmusclecells,VSMCs)的增殖状态 ;应用流式细胞术测定细胞周期 ;利用p4 4 / 4 2磷酸化抗MAPK抗体的蛋白免疫印迹法测定MAPK蛋白表达。结果显示 :( 1)TNF α处理组与对照组相比 ,TNF α对VSMC增殖具有明显的刺激作用 (P <0 0 5 )。rhIL 10单独应用对VSMCs生长没有影响 (P >0 0 5 )。在TNF α刺激下 ,低至 10ng/ml的rhIL 10可抑制VSMCs的生长 (P <0 0 5 )。流式细胞术测定的结果显示 ,rhIL 10分别可使TNF α作用下的VSMC大部分处于G0 /G1期 ,与对照组相比有明显差异 (P <0 0 1)。 ( 2 )TNF α对p4 4 /p4 2MAPK蛋白表达有显著的增强作用 ,此作用可被rhIL 10抑制。结果提示 ,rhIL 10可抑制TNF α诱导的VSMC增殖及p4 4 /p4 2丝裂素活化蛋白激酶的表达